Ryan Watkins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ryan Watkins has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Doug Leigh
Pepperdine University
5 shared publications - Soheil Human
Vienna University of Economics and Business
4 shared publications - Roger Kaufman
Florida State University
3 shared publications - Don Triner
United States Coast Guard Academy
2 shared publications - Kristin Marsh Song
World Bank
2 shared publications - Akhilesh Pandey
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication
Latest Publications
- 15 August 2026
- Published by Springer Nature
- p. 625-641
LLMs in Research: Opportunities, Risks, and Ethics in the Age of AI-Augmented Science
- 15 August 2026
- Published by Springer Nature
- p. 625-641
LLMs in Research: Opportunities, Risks, and Ethics in the Age of AI-Augmented Science
- 4 December 2025
- Published by Wiley in Journal of Engineering Education
- Vol. 115 (1)
Recommendations for the integration of generative artificial intelligence in support of engineering education research workflows
- 4 December 2025
- Published by Wiley in Journal of Engineering Education
- Vol. 115 (1)
Recommendations for the integration of generative artificial intelligence in support of engineering education research workflows
- 5 December 2024
- Published by Taylor & Francis in Creativity Research Journal
- Vol. 38 (1) , 137-149
AI’s Influence on Human Creative Agency
- 5 December 2024
- Published by Taylor & Francis in Creativity Research Journal
- Vol. 38 (1) , 137-149
AI’s Influence on Human Creative Agency
- 1 December 2023
- Published by Springer Nature
- p. 85-112
ATIAS: A Model for Understanding Intentions to Use AI Technology
- 1 December 2023
- Published by Springer Nature
- p. 85-112
ATIAS: A Model for Understanding Intentions to Use AI Technology
- Open Access
- 16 May 2023
- Published by Springer Nature in AI and Ethics
- Vol. 4 (4) , 969-974
Guidance for researchers and peer-reviewers on the ethical use of Large Language Models (LLMs) in scientific research workflows
- 16 May 2023
- Published by Springer Nature in AI and Ethics
- Vol. 4 (4) , 969-974
Open AccessGuidance for researchers and peer-reviewers on the ethical use of Large Language Models (LLMs) in scientific research workflows
- Open Access
- 6 October 2022
- Published by Springer Nature in AI and Ethics
- Vol. 3 (3) , 811-826
Needs and artificial intelligence
Throughout our history, we, Homo sapiens, have used technologies to better satisfy ourneeds. The relation betweenneedsandtechnologyis so fundamental that the US National Research Council defines the distinguishing characteristic of technology as its goal “to make modifications in the world [in order] to meet human needs” [1]. Artificial intelligence (AI) is one of the most promising emerging technologies of our time. Similar to other technologies, AI is expected by many “to meet [human] needs”. In this article, we reflect on the relationship betweenneedsand AI, and call for the realization ofneeds-awareAI systems. We argue that re-thinkingneedsfor,through,by, andwithAI can be a very useful means towards the development of realistic approaches for sustainableHuman-aware,Accountable,Lawful, andEthical (HALE) AI systems. We discuss some of the most critical gaps, barriers, enablers, and drivers of co-creating future AI-based sociotechnical systems in which [human]needsare well considered and met. Finally, we provide an overview of potential challenges and considerations that should be carefully taken into account; and call for joint, immediate, and interdisciplinary efforts and collaborations to start on the path toneeds-awareAI.
- 6 October 2022
- Published by Springer Nature in AI and Ethics
- Vol. 3 (3) , 811-826
Open AccessNeeds and artificial intelligence
Throughout our history, we, Homo sapiens, have used technologies to better satisfy ourneeds. The relation betweenneedsandtechnologyis so fundamental that the US National Research Council defines the distinguishing characteristic of technology as its goal “to make modifications in the world [in order] to meet human needs” [1]. Artificial intelligence (AI) is one of the most promising emerging technologies of our time. Similar to other technologies, AI is expected by many “to meet [human] needs”. In this article, we reflect on the relationship betweenneedsand AI, and call for the realization ofneeds-awareAI systems. We argue that re-thinkingneedsfor,through,by, andwithAI can be a very useful means towards the development of realistic approaches for sustainableHuman-aware,Accountable,Lawful, andEthical (HALE) AI systems. We discuss some of the most critical gaps, barriers, enablers, and drivers of co-creating future AI-based sociotechnical systems in which [human]needsare well considered and met. Finally, we provide an overview of potential challenges and considerations that should be carefully taken into account; and call for joint, immediate, and interdisciplinary efforts and collaborations to start on the path toneeds-awareAI.
- 27 June 2022
- Published by Springer Nature in AI and Ethics
- Vol. 3 (1) , 49-52
Needs-aware artificial intelligence: AI that ‘serves [human] needs’
- 27 June 2022
- Published by Springer Nature in AI and Ethics
- Vol. 3 (1) , 49-52
Needs-aware artificial intelligence: AI that ‘serves [human] needs’
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 3094
Abstract 3094: Proteomic profiling of cholangiocarcinoma predicts response to a novel small molecule inhibitor in preclinical models
Background: Cholangiocarcinoma is an aggressive malignancy with limited systemic therapeutics. We have recently identified LCK, a non-receptor tyrosine kinase, as a potential therapeutic target in select subtypes of cholangiocarcinoma. Proteomic profiling in other cancer types has proven beneficial in predicting response to systemic therapies. Herein, we present proteomic profiling of cholangiocarcinoma can predict sensitivity to a novel LCK inhibitor in patient derived xenograft models. Methods: Proteins from 28 unique cholangiocarcinoma patient derived xenograft models (PDX) were isolated, labeled with tandem mass tags (TMT) and then analyzed by liquid chromatography and mass spectroscopy (LC/MS). Phosphopeptides were separately evaluated both by Immobilized Metal Affinity Chromatography and pY-enrichment techniques. Following normalization, the global proteome, serine/threonine phosphoproteome, and tyrosine phosphoproteome were analyzed and a proteomic signature was created for each tumor. These signatures were compared to PDX models with known response profiles to NTRC0652-0, an LCK inhibitor (1 resistant and 1 sensitive). The top 200 differentially abundant proteins (log2FC 2.6) were then utilized to develop a sensitive and a resistant signature. Correlation indices were then calculated across the 28 PDX model library. An additional predicted resistant and predicted sensitive model was expanded. Tumor bearing mice were randomized based on tumor volume to either treatment with NTRC (30mg/kg PO daily), n=5, or vehicle, n=4, (10% Kolliphor, 10% DMSO, 80% Water, 2 mol equivalents HCl). Tumors were measured weekly with calipers and then weighed at the end of the study. Results: In the top 200 differentially abundant proteins that represented the proteomic signature there was over representation of proteins with decreased abundance. There were only 12 proteins with higher abundance in the sensitive model as compared to the resistant. Utilizing the signature developed from the global proteomics data, nine tumors were predicted to be sensitive while 17 were predicted to be resistant to NTRC. PDX115 is a an intrahepatic CCA PDX known to contain an IDH1 mutation and was predicted to be resistant by modeling. The model was resistant to single agent NTRC with no demonstrable effect on tumor growth in vivo. PDX175 is a distal CCA PDX and was predicted to be sensitive by modeling. In vivo growth was inhibited by NTRC as compared to vehicle treated mice following two weeks of treatment (983% vs 435%, p=0.03). Additionally, final tumor weight was significantly lower in NTRC treated mice (0.651 g vs 0.317 g, p=0.04). Conclusion: Cholangiocarcinoma proteomic signatures can be used to predict therapeutic response to a novel LCK inhibitor in preclinical models. Whether or not this could be applied to other treatment modalities in cholangiocarcinoma remains to be determined. Citation Format: Ryan Watkins, Roberto Alva-Ruiz, Caitlin Conboy, Dong-Gi Mun, Erik Jessen, Diep Vu, Jos de Man, Rogier Buijsman, Akhilesh Pandey, Mitesh Borad, Gregory Gores, Rory Smoot. Proteomic profiling of cholangiocarcinoma predicts response to a novel small molecule inhibitor in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3094.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 3094
Open AccessAbstract 3094: Proteomic profiling of cholangiocarcinoma predicts response to a novel small molecule inhibitor in preclinical models
Background: Cholangiocarcinoma is an aggressive malignancy with limited systemic therapeutics. We have recently identified LCK, a non-receptor tyrosine kinase, as a potential therapeutic target in select subtypes of cholangiocarcinoma. Proteomic profiling in other cancer types has proven beneficial in predicting response to systemic therapies. Herein, we present proteomic profiling of cholangiocarcinoma can predict sensitivity to a novel LCK inhibitor in patient derived xenograft models. Methods: Proteins from 28 unique cholangiocarcinoma patient derived xenograft models (PDX) were isolated, labeled with tandem mass tags (TMT) and then analyzed by liquid chromatography and mass spectroscopy (LC/MS). Phosphopeptides were separately evaluated both by Immobilized Metal Affinity Chromatography and pY-enrichment techniques. Following normalization, the global proteome, serine/threonine phosphoproteome, and tyrosine phosphoproteome were analyzed and a proteomic signature was created for each tumor. These signatures were compared to PDX models with known response profiles to NTRC0652-0, an LCK inhibitor (1 resistant and 1 sensitive). The top 200 differentially abundant proteins (log2FC 2.6) were then utilized to develop a sensitive and a resistant signature. Correlation indices were then calculated across the 28 PDX model library. An additional predicted resistant and predicted sensitive model was expanded. Tumor bearing mice were randomized based on tumor volume to either treatment with NTRC (30mg/kg PO daily), n=5, or vehicle, n=4, (10% Kolliphor, 10% DMSO, 80% Water, 2 mol equivalents HCl). Tumors were measured weekly with calipers and then weighed at the end of the study. Results: In the top 200 differentially abundant proteins that represented the proteomic signature there was over representation of proteins with decreased abundance. There were only 12 proteins with higher abundance in the sensitive model as compared to the resistant. Utilizing the signature developed from the global proteomics data, nine tumors were predicted to be sensitive while 17 were predicted to be resistant to NTRC. PDX115 is a an intrahepatic CCA PDX known to contain an IDH1 mutation and was predicted to be resistant by modeling. The model was resistant to single agent NTRC with no demonstrable effect on tumor growth in vivo. PDX175 is a distal CCA PDX and was predicted to be sensitive by modeling. In vivo growth was inhibited by NTRC as compared to vehicle treated mice following two weeks of treatment (983% vs 435%, p=0.03). Additionally, final tumor weight was significantly lower in NTRC treated mice (0.651 g vs 0.317 g, p=0.04). Conclusion: Cholangiocarcinoma proteomic signatures can be used to predict therapeutic response to a novel LCK inhibitor in preclinical models. Whether or not this could be applied to other treatment modalities in cholangiocarcinoma remains to be determined. Citation Format: Ryan Watkins, Roberto Alva-Ruiz, Caitlin Conboy, Dong-Gi Mun, Erik Jessen, Diep Vu, Jos de Man, Rogier Buijsman, Akhilesh Pandey, Mitesh Borad, Gregory Gores, Rory Smoot. Proteomic profiling of cholangiocarcinoma predicts response to a novel small molecule inhibitor in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3094.
- Open Access
Needs-aware Artificial Intelligence: AI that 'serves [human] needs'
By defining the current limits (and thereby the frontiers), many boundaries are shaping, and will continue to shape, the future of Artificial Intelligence (AI). We push on these boundaries in order to make further progress into what were yesterday's frontiers. They are both pliable and resilient - always creating new boundaries of what AI can (or should) achieve. Among these are technical boundaries (such as processing capacity), psychological boundaries (such as human trust in AI systems), ethical boundaries (such as with AI weapons), and conceptual boundaries (such as the AI people can imagine). It is within this final category while it can play a fundamental role in all other boundaries} that we find the construct of needs and the limitations that our current concept of need places on the future AI.
Open AccessNeeds-aware Artificial Intelligence: AI that 'serves [human] needs'
By defining the current limits (and thereby the frontiers), many boundaries are shaping, and will continue to shape, the future of Artificial Intelligence (AI). We push on these boundaries in order to make further progress into what were yesterday's frontiers. They are both pliable and resilient - always creating new boundaries of what AI can (or should) achieve. Among these are technical boundaries (such as processing capacity), psychological boundaries (such as human trust in AI systems), ethical boundaries (such as with AI weapons), and conceptual boundaries (such as the AI people can imagine). It is within this final category while it can play a fundamental role in all other boundaries} that we find the construct of needs and the limitations that our current concept of need places on the future AI.
- Open Access
Needs and Artificial Intelligence
Throughout their history, homo sapiens have used technologies to better satisfy their needs. The relation between needs and technology is so fundamental that the US National Research Council defined the distinguishing characteristic of technology as its goal "to make modifications in the world to meet human needs". Artificial intelligence (AI) is one of the most promising emerging technologies of our time. Similar to other technologies, AI is expected "to meet [human] needs". In this article, we reflect on the relationship between needs and AI, and call for the realisation of needs-aware AI systems. We argue that re-thinking needs for, through, and by AI can be a very useful means towards the development of realistic approaches for Sustainable, Human-centric, Accountable, Lawful, and Ethical (HALE) AI systems. We discuss some of the most critical gaps, barriers, enablers, and drivers of co-creating future AI-based socio-technical systems in which [human] needs are well considered and met. Finally, we provide an overview of potential threats and HALE considerations that should be carefully taken into account, and call for joint, immediate, and interdisciplinary efforts and collaborations.
Open AccessNeeds and Artificial Intelligence
Throughout their history, homo sapiens have used technologies to better satisfy their needs. The relation between needs and technology is so fundamental that the US National Research Council defined the distinguishing characteristic of technology as its goal "to make modifications in the world to meet human needs". Artificial intelligence (AI) is one of the most promising emerging technologies of our time. Similar to other technologies, AI is expected "to meet [human] needs". In this article, we reflect on the relationship between needs and AI, and call for the realisation of needs-aware AI systems. We argue that re-thinking needs for, through, and by AI can be a very useful means towards the development of realistic approaches for Sustainable, Human-centric, Accountable, Lawful, and Ethical (HALE) AI systems. We discuss some of the most critical gaps, barriers, enablers, and drivers of co-creating future AI-based socio-technical systems in which [human] needs are well considered and met. Finally, we provide an overview of potential threats and HALE considerations that should be carefully taken into account, and call for joint, immediate, and interdisciplinary efforts and collaborations.